Regent Investment Management LLC boosted its position in Allergan PLC. (NYSE:AGN) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,569 shares of the company’s stock after buying an additional 231 shares during the period. Regent Investment Management LLC’s holdings in Allergan PLC. were worth $1,840,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. GWM Advisors LLC increased its position in shares of Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after buying an additional 5 shares in the last quarter. Burns J W & Co. Inc. NY increased its position in shares of Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after buying an additional 6 shares in the last quarter. Trust Co increased its position in shares of Allergan PLC. by 0.7% in the fourth quarter. Trust Co now owns 1,214 shares of the company’s stock worth $255,000 after buying an additional 9 shares in the last quarter. JNBA Financial Advisors increased its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Finally, Tarbox Group Inc. increased its position in shares of Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock worth $572,000 after buying an additional 15 shares in the last quarter. Institutional investors and hedge funds own 84.77% of the company’s stock.
Shares of Allergan PLC. (NYSE:AGN) traded up 0.29% on Friday, hitting $232.88. The stock had a trading volume of 1,820,899 shares. The firm has a 50 day moving average of $245.93 and a 200 day moving average of $238.13. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock has a market cap of $78.06 billion, a P/E ratio of 7.10 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the business earned $3.35 earnings per share. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, equities analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
Several research firms have recently issued reports on AGN. UBS AG restated a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a report on Monday, June 26th. Wells Fargo & Company restated an “outperform” rating and set a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a report on Wednesday, May 10th. Finally, Royal Bank Of Canada upped their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a report on Wednesday, May 10th. Eight analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $274.49.
In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.36% of the stock is owned by insiders.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.